Circulating tumor cells after neoadjuvant chemotherapy are related with recurrence in esophageal squamous cell carcinoma.
Circulating tumor cells
Epithelial–mesenchymal transition
Esophageal squamous cell carcinoma
Neoadjuvant chemotherapy
Journal
Esophagus : official journal of the Japan Esophageal Society
ISSN: 1612-9067
Titre abrégé: Esophagus
Pays: Japan
ID NLM: 101206627
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
29
11
2020
accepted:
25
02
2021
pubmed:
5
3
2021
medline:
26
3
2022
entrez:
4
3
2021
Statut:
ppublish
Résumé
Circulating tumor cells (CTCs) are known to be a systemic process of malignant progression of cancer cells and there is a possibility that analysis for CTCs as a liquid biopsy become predictive or prognostic tools for cancer patients. In the present study with the novel CTCs detection system (Celsee system At the baseline, there are detectable amounts of CTCs in all patients (n = 30) at all stages, and there were no significant differences of total CTCs, E-CTCs, or M-CTCs numbers between stages. Of importance, among total CTCs, M-CTCs are more dominant than E-CTCs in number. Also, there was no significant change of detectable amounts and phenotype of CTCs before and after NAC (n = 24). Of note, early recurrent group indicated that there was an elevated total CTCs number before NAC and an increased M-CTCs after NAC in comparison to those in non-recurrent group. Quantitative and qualitative analysis of CTCs may provide useful complementary predictive and prognostic information in ESCC.
Sections du résumé
BACKGROUND
Circulating tumor cells (CTCs) are known to be a systemic process of malignant progression of cancer cells and there is a possibility that analysis for CTCs as a liquid biopsy become predictive or prognostic tools for cancer patients.
METHODS
In the present study with the novel CTCs detection system (Celsee system
RESULTS
At the baseline, there are detectable amounts of CTCs in all patients (n = 30) at all stages, and there were no significant differences of total CTCs, E-CTCs, or M-CTCs numbers between stages. Of importance, among total CTCs, M-CTCs are more dominant than E-CTCs in number. Also, there was no significant change of detectable amounts and phenotype of CTCs before and after NAC (n = 24). Of note, early recurrent group indicated that there was an elevated total CTCs number before NAC and an increased M-CTCs after NAC in comparison to those in non-recurrent group.
CONCLUSIONS
Quantitative and qualitative analysis of CTCs may provide useful complementary predictive and prognostic information in ESCC.
Identifiants
pubmed: 33661456
doi: 10.1007/s10388-021-00829-x
pii: 10.1007/s10388-021-00829-x
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
566-573Références
Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–12.
doi: 10.1016/S0140-6736(12)60643-6
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-386.
doi: 10.1002/ijc.29210
Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2010. Esophagus. 2017;14(3):189–214.
doi: 10.1007/s10388-017-0578-4
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.
doi: 10.1056/NEJMoa1112088
Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8(6):545–53.
doi: 10.1016/S1470-2045(07)70172-9
Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013;14(7):627–37.
doi: 10.1016/S1470-2045(13)70136-0
Kono K, Mimura K, Yamada R, et al. Current status of cancer immunotherapy for esophageal squamous cell carcinoma. Esophagus. 2018;15(1):1–9.
doi: 10.1007/s10388-017-0596-2
Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57.
doi: 10.1016/S0140-6736(18)32557-1
Quhal F, Mori K, Sari Motlagh R, et al. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. Int J Clin Oncol. 2020;25(6):1037–54.
doi: 10.1007/s10147-020-01650-9
Shien T, Iwata H. Adjuvant and neoadjuvant therapy for breast cancer. Jpn J Clin Oncol. 2020;50(3):225–9.
doi: 10.1093/jjco/hyz213
Uprety D, Mandrekar SJ, Wigle D, Roden AC, Adjei AA. Neoadjuvant immunotherapy for non-small cell lung cancer - current concepts and future approaches. J Thorac Oncol. 2020;15(8):1281–97.
doi: 10.1016/j.jtho.2020.05.020
Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74.
doi: 10.1245/s10434-011-2049-9
Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16(1):25–43.
doi: 10.1007/s10388-018-0642-8
Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.
doi: 10.1016/S1470-2045(15)00040-6
Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2015;7(1):1–11.
doi: 10.15252/emmm.201303698
Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell. 2016;166(1):21–45.
doi: 10.1016/j.cell.2016.06.028
Thar Min AK, Okayama H, Saito M, et al. Epithelial-mesenchymal transition-converted tumor cells can induce T-cell apoptosis through upregulation of programmed death ligand 1 expression in esophageal squamous cell carcinoma. Cancer Med. 2018;7(7):3321–30.
doi: 10.1002/cam4.1564
de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–9.
doi: 10.1158/1078-0432.CCR-08-0872
Bidard FC, Michiels S, Riethdorf S, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst. 2018;110(6):560–7.
doi: 10.1093/jnci/djy018
Hall C, Karhade M, Laubacher B, et al. Circulating tumor cells after neoadjuvant chemotherapy in stage I-III triple-negative breast cancer. Ann Surg Oncol. 2015;22(Suppl 3):S552-558.
doi: 10.1245/s10434-015-4600-6
Ko JMY, Ng HY, Lam KO, et al. Liquid biopsy serial monitoring of treatment responses and relapse in advanced esophageal squamous cell carcinoma. Cancers. 2020;12(6):1352.
doi: 10.3390/cancers12061352
Zhao Y, Han L, Zhang W, et al. Preoperative chemotherapy compared with postoperative adjuvant chemotherapy for squamous cell carcinoma of the thoracic oesophagus with the detection of circulating tumour cells randomized controlled trial. Int J Surg. 2020;73:1–8.
doi: 10.1016/j.ijsu.2019.11.005
Gogoi P, Sepehri S, Zhou Y, et al. Development of an automated and sensitive microfluidic device for capturing and characterizing circulating tumor cells (CTCs) from clinical blood samples. PLoS ONE. 2016;11(1):e0147400.
doi: 10.1371/journal.pone.0147400
Shaw Bagnall J, Byun S, Begum S, et al. Deformability of tumor cells versus blood cells. Sci Rep. 2015;5:18542.
doi: 10.1038/srep18542
Kou R, Zhao J, Gogoi P, et al. Enrichment and mutation detection of circulating tumor cells from blood samples. Oncol Rep. 2018;39(6):2537–44.
pubmed: 29620284
pmcid: 5983925
Li Y, Wu G, Yang W, et al. Prognostic value of circulating tumor cells detected with the cell search system in esophageal cancer patients: a systematic review and meta-analysis. BMC Cancer. 2020;20(1):581.
doi: 10.1186/s12885-020-07059-x
Aktas B, Kasimir-Bauer S, Heubner M, Kimmig R, Wimberger P. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. Int J Gynecol Cancer. 2011;21(5):822–30.
doi: 10.1097/IGC.0b013e318216cb91
Heitzer E, Auer M, Gasch C, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013;73(10):2965–75.
doi: 10.1158/0008-5472.CAN-12-4140
Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580–4.
doi: 10.1126/science.1228522
Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1–2):349–61.
doi: 10.1016/j.cell.2011.11.025
Satelli A, Batth I, Brownlee Z, et al. EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression. Oncotarget. 2017;8(30):49329–37.
doi: 10.18632/oncotarget.17632
Chebouti I, Kasimir-Bauer S, Buderath P, et al. EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy. Oncotarget. 2017;8(30):48820–31.
doi: 10.18632/oncotarget.16179
Satelli A, Mitra A, Brownlee Z, et al. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res. 2015;21(4):899–906.
doi: 10.1158/1078-0432.CCR-14-0894
Shaw JA, Guttery DS, Hills A, et al. Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high circulating tumor cell counts. Clin Cancer Res. 2017;23(1):88–96.
doi: 10.1158/1078-0432.CCR-16-0825